Endo provides more info on oxymorphone ER and IR tablets

January 2, 2006

Endo Pharmaceuticals has responded to the FDA's request for more information on the company's application for the investigational painkillers oxymorphone extended-release (ER) and immediate-release (IR) tablets. The FDA requested additional clinical trials to further confirm the safety and efficacy of the products after issuing approval letters in October 2003. If its product is approved, Endo said it's prepared to launch oxymorphone in the second half of 2006.

Endo Pharmaceuticals has responded to the FDA's request for more information on the company's application for the investigational painkillers oxymorphone extended-release (ER) and immediate-release (IR) tablets. The FDA requested additional clinical trials to further confirm the safety and efficacy of the products after issuing approval letters in October 2003. If its product is approved, Endo said it's prepared to launch oxymorphone in the second half of 2006.